Glaukos Posts Record Q2 Sales on Strong Glaucoma Product Growth
Event summary
- Glaukos reported Q2 2026 net sales of $185.6M, up 50% YoY.
- U.S. glaucoma product sales surged 64% YoY to $118.5M.
- Company raised full-year revenue guidance to $680M-$700M from prior $620M-$635M range.
- Non-GAAP gross margin improved to 85% from 83% in Q2 2025.
- Operating loss narrowed to $17.3M from $22.7M year-over-year.
The big picture
Glaukos's strong quarter reflects successful commercialization of its dropless glaucoma therapies, positioning it as a key player in ophthalmic innovation. The company's ability to expand margins while increasing R&D investment suggests strategic focus on long-term product development over short-term profitability. This performance comes amid growing competition in the glaucoma treatment space and increasing demand for minimally invasive solutions.
What we're watching
- Product Momentum
- How Glaukos will sustain growth of iDose TR and Epioxa therapies in competitive glaucoma market.
- Execution Risk
- Whether the company can maintain operational efficiency amid 34-40% increases in SG&A and R&D expenses.
- Market Expansion
- The pace at which international glaucoma sales will grow following 17.2% YoY increase in Q2.